This association between CD99 expression and chemoresistance in refractory and early relapsed AML patients was further validated through an integrated single-cell RNA sequencing (scRNA-seq) analysis of bone marrow samples from AML patients. The gene discussed is CD99; the disease is acute myeloid leukemia.